# NOCD

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nocd

- Industry: Software
- Headquarters: Chicago, US
- Website: www.treatmyocd.com
- Total disclosed funding: $81M
- Latest round: Series C (Jan 18, 2023)
- Investors on record: 10

## About

NOCD, Inc. provides specialized therapy for Obsessive-Compulsive Disorder (OCD) through its evidence-based Exposure and Response Prevention therapy, delivered via virtual sessions with trained therapists, enhancing accessibility to treatment.Founded in 2017 in Chicago, US, NOCD, Inc. focuses on delivering therapy for OCD. The company has successfully raised funding through 6 deals, including its most recent Series C round on January 18, 2023, where it secured USD 30.44 mn. The founders are Ilyas Patanam and Stephen Smith, with Stephen serving as the CEO. NOCD has not undergone any significant pivots or changes in ownership structure since its inception.NOCD primarily offers evidence-based therapy for Obsessive-Compulsive Disorder (OCD) through its flagship product, Exposure and Response Prevention (ERP) therapy. The effectiveness of ERP therapy is supported by extensive peer-reviewed research. Services are provided through virtual sessions with trained therapists, promoting accessibility for individuals of various backgrounds and ages experiencing OCD. NOCD’s offerings are mainly marketed in the United States, with an expanding presence in international markets.NOCD generates revenue via a subscription model where clients pay for therapy sessions and related services. These transactions involve direct interactions with licensed therapists through live video sessions specializing in OCD treatment. The company also provides an app for ongoing support and virtual resources, enhancing the therapeutic experience. NOCD accepts various insurance plans to widen its client reach, ensuring treatment accessibility while maintaining financial viability.In January 2023, NOCD, Inc. raised USD 30.44 mn in a funding round co-led by Cigna Ventures and 7-Wire Ventures, along with participation from Longitude Capital and other investors. The funding will be utilized to expand its network of OCD-specialty therapists, refine public perception of OCD in collaboration with Howie Mandel and the #KnowOCD campaign, and improve analytics and outcomes capabilities for payers aiming to enhance offerings for OCD populations. The company plans to further penetrate the market by enhancing its services and exploring international expansion opportunities.

## Funding rounds

- Series C, Jan 18, 2023, $30M — Eight Roads Ventures, F-Prime Capital, Longitude Capital, Health Enterprise Partners, Kaiser Permanente Ventures, 7wireVentures, Cigna Ventures
- Series B, Sep 21, 2021, $33M — Eight Roads Ventures, F-Prime Capital, Health Enterprise Partners, Chicago Ventures, Kaiser Permanente Ventures, 7wireVentures
- Series A, Oct 8, 2020, $12M — Health Enterprise Partners, Chicago Ventures, Hyde Park Angels, 7wireVentures
- Series A, Sep 25, 2019, $4M — Chicago Ventures, Hyde Park Angels, 7wireVentures, Meridian Street Capital
- Seed, Dec 27, 2017, $1M — 7wireVentures

## Investors

- 7wireVentures (https://capitalatlas.ai/funds/7wireventures) — Seed, Series A, Series B, Series C
- Chicago Ventures (https://capitalatlas.ai/funds/chicago-ventures) — Series A, Series B
- Hyde Park Angels (https://capitalatlas.ai/funds/hyde-park-angels) — Series A
- Meridian Street Capital (https://capitalatlas.ai/funds/meridian-street-capital) — Series A
- Health Enterprise Partners (https://capitalatlas.ai/funds/health-enterprise-partners) — Series A, Series B, Series C
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B, Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B, Series C
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series B, Series C
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series C
- Cigna Ventures (https://capitalatlas.ai/funds/cigna-ventures) — Series C